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Abstract 
Site-directed mutagenesis of the three binding sites for the mammary factor MPBF in the/I-lactoglobulin (BLG) promoter demonstrates that MPBF 
is a transcriotional activator of the BLG gene in mammarv cells. MPBF requires Dhosphorvlation on tvrosine for maximum binding activitv and 
binds to C&S (interferon y-activation sitejelements which ire similar to the hPBF binding sites. Prolaciin induces MPBF binding activity inCH0 
cells and is not antigenically related to Stat1 (~91) and Stat2 (pll3), suggesting that this transcription factor is likely to be another member of the 
STAT family of cytokine/growth factor-induced transcription factors. 
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1. Introduction 
Prolactin (PRL) is a peptide hormone that regulates 
the metabolism, proliferation and differentiation of a 
variety of cells and tissues [l]. In the mammary gland, 
PRL controls both development of the gland and the 
expression of milk protein genes [2]. The PRL receptor 
is closely related to the growth hormone (GH) receptor 
and is a member of the cytokine/GH superfamily of re- 
ceptors that lack intrinsic tyrosine kinase activity [3]. 
Upon GH binding, the GH receptor associates with, and 
is phosphorylated by JAK2, a non-receptor protein tyro- 
sine kinase (PTK), which is presumed to initiate the sig- 
nal cascade that results in gene activation [4,5]. The re- 
cent demonstration that JAK2 is also essential for both 
IFN [6] and PRL [7] signal transduction suggests that 
PRL action may be mediated through a member of the 
STAT family of transcription factors which are involved in 
IFN and cytokine signalling pathways (reviewed in [8]). 
The putative mammary transcription factor MPBF 
has three binding sites within the proximal 410 bp pro- 
moter of the sheep p-lactoglobulin (BLG) gene [9]. 
MPBF may be related to the transcription factor MGF 
which has been shown to be essential for the hormone 
induced transcription of a transfected B-casein promoter/ 
CAT construct in mammary HCl 1 cells [lo]. The highest 
affinity MPBF binding site GATTCCGGGAACC is 
similar to the IFN-y activation sequence (GAS) ATA- 
TTCCTGTAAGTG in the Ly-6E gene [l 1 J and shares 
an identical 9 bp core with a high affinity acute phase 
response factor (APRF) binding site [12]. This suggests 
that MPBF could be related to the IFN-)/ activated fac- 
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Abbreviations: IFN, interferon; EMSA, electrophoretic mobility shift 
assay; CAT, chloramphenicol acetyl transferase. 
tor, Stat 1, or to other members of the STAT family of 
transcription factors. STAT factors are latent cytoplas- 
mic transcription factors that are activated by phospho- 
rylation on tyrosine resulting in dimerisation and 
translocation of the complex into the nucleus where it 
binds target DNA [ 131. 
We demonstrate here that MPBF is a transcriptional 
activator of the BLG gene in mammary cells. We also 
show that MPBF is induced in HCl1 cells in response to 
dexamethasone and PRL and in CHO cells in response 
to PRL alone. MPBF is not antigenically related to Stat1 
or Stat2, but is phosphorylated on tyrosine and binds to 
GAS elements suggesting that it is probably a 
factor which mediates the response to prolactin. 
STAT 
2. Materials and methods 
2.1. BLG reporter constructs and plasmids 
Individual MPBF binding sites in the BLG promoter were mutated 
as described ([14], T.B. et al., in prep.). The mutated BLG promoters 
were excised as Sal I/ SphI fragments and cloned 5’ of the CAT gene 
in SalUSphI restricted CAT/pUC19 plasmid. The NFkB site at -172 
in the BLG promoter was mutated using the same stategy as described 
for generating the MPBF mutations. Sequences of the mutant oli- 
gonucleotides are: STMm(sense) GGGATTTGGCCAACCGC; -- 
STMm(antisense) GCGGTTGGCCAAATCCC; A3m(sense) GTCT- -7 
ACCACCAACCGTC; A3m(antlsense) GACGGTTGGTGGTA- 
GAC; Alm(sense) GTGTTCCTCCCACTGGC; Alm(antisense) 
GCCAGTGGGAGGAACAC; NxBm(sense) GGCCCAGAG- 
EGACTTBTG; NFkBm(antisense) CAGGAAGTCGAGCTCT- 
GGGCC The bases which have been changed are underlined. 
2.2. CAT assays 
Before harvesting, cells were washed with phosphate buffered saline, 
then scraped from the dishes in 10 mM Tris-HCl, pH 7.5,30 mM NaCl, 
1 mM EDTA. Cells were pelleted by centrifugation and resuspended 
in 200~1 of 0.25 M Tris-HCl. Cytosol extracts were prepared by 3 cycles 
of freeze thawing [I 51 followed by centrifugation at 10,000 x g for 5 min. 
The protein concentration f the supernatants was estimated using the 
BCA protein assay (Pierce). CAT assays containing 1 pg of protein 
extract were carried out as described previously [15] and assayed using 
thin layer chromatography. 
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2.3. Cell culture and transfection 
The growth and hormonal induction of HCl I mammary cells was 
carried out as previously described [IO]. Approximately 5 x lo5 cells per 
80 cm2 flask were cotransfected overnight with 1 pg of pSV2neo and 
15 pug of BLG plasmid by calcium phosphate precipitation [15]. After 
14 days of selection in growth medium containing 200 ,@ml G418, 
colonies were trypsinised and expanded as a pool of clones. Pools 
containing greater than 100 colonies were utilised in the hormone in- 
duction experiments. The CHO-E3 cell line is a clone derived from 
CHO-KI cells stably transfected with the rabbit long-form PRL recep- 
tor and was a kind gift from Jean Djiane, INRA, Jouy-en-Josas, 
France. CHO-E3 cells were induced in serum free medium with PRL 
as described previously [16]. 
2.4. Nuclear extracts and EMSA 
Nuclear extracts were prepared from tissues and cells using the 
method of Dignam [17] with minor modifications [9]. Aliquots were 
flash frozen in liquid nitrogen and stored at -80°C. Daudi cells (human 
lymphoma derived) were treated with 1000 units IFN-a/ml for 2 h 
before preparation of nuclear extract. Daudi extracts were generously 
provided by John Girdlestone, Laboratory of Molecular Biology, Cam- 
bridge. EMSAs were carried out as previously described [9] and where 
indicated, unlabelled oligonucleotide competitors were added 
simultaneously. Binding sites were created by annealing the following 
oligonucleotide pairs: STM GATTCCGGGkACCGC? and ACGCI 
GGTTCCCGGAATC: SIE GTCGACATTTCCCGTAAATC and 
TCGACGATTTACGGGAAATG; GAS CATGTTATGCATATTC- 
CTGTAAGTG and CATGCACITACAGGAATATGCATAA; ISRE 
GATCGGGAAAGGGAAACCGAAACTGAAGCC and GATCGG- 
CTTCAGTTTCGGTTTCCCTTTCCC. Supershift analysis was car- 
ried out essentially as above with prior incubation of antibody and 
nuclear extract for 30 min at 4°C plus 10 min at 25°C before the 
addition of probe. The Stat1 antibody was purchased from Transduc- 
tion Laboratories and the Stat2 antibody was the gift of Chris 
Schindler, Columbia University, New York. 
2.5. Phosphorylation studies of MPBF 
Two protein tyrosine phosphatases were used, T-Cell, (NEB: a 
human T-cell tyrosine phosphatase) and LAR (NEB; the human trans- 
membrane leukocyte antigen related tyrosine phosphatase). Sheep nu- 
clear extract (250 ng) was incubated at 30°C for 20-60 min with 5 U 
of the T-Cell, (167 ng) or LAR (1.25 pg) phosphatase, after which 
EMSA was carried out on the extracts. Monoclonal anti-phosphoty- 
rosine, anti-phosphoserine and anti-phosphothreonine antibodies 
(Sigma) or control mouse ascites fluid (2-5 pug) were incubated on ice 
for 90 min with approximately 100 ng partially purified MPBF (from 
sheep lactating mammary gland nuclei) in gel shift buffer and then 
analysed by EMSA. 
2.6. UV cross-linking of MPBF 
The double-stranded DNA probe used in the cross-linking experi- 
ment was prepared as described in Wakao [18] by annealing the single- 
strand oligonucleotide that spans the STM binding site (TGGGATT- 
CCGGGAACCGCGTA(A),,) with a short primer (TTACGCGG). 
MPBF was cross-linked to the oligonucleotide probe by irradiation of 
an EMSA gel on a UV transilluminator for 2 min. To reduce the 
exposure times required to detect cross-linked proteins by autoradi- 
ography, electroelution was eliminated by incorporating the EMSA gel 
slice into the stacking gel of an SDS-PAGE gel [19]. Labelled polypep- 
tides were detected by autoradiography of dried gels. 
2.7. Quantitation 
Data were quantitated with a Molecular Dynamics PhosphorImager 
system. 
3. Results 
3.1. MPBF is a transcriptional activator of BLG 
promoter constructs in mammary HCIl cells 
Electrophoretic mobility shift assay (EMSA) with nu- 
clear extracts prepared from hormonally induced HCl 1 
cells and the high affinity STM binding site from the 
BLG promoter revealed a specific MPBF complex in 
HCl 1 cells. This MPBF-like activity was present at low 
levels in uninduced HCl 1 cells (Fig. 1 A, lane 1) and was 
induced 2- to 3-fold by treating cells with dexamethasone 
(DEX) and PRL (lane 2). 
To determine the role of MPBF in the transcriptional 
regulation of the BLG gene in mammary cells, the 408 
bp BLG proximal promoter sequence was mutated to 
abrogate MPBF binding at combinations of binding sites 
within a BLGKAT reporter gene construct. To abolish 
MPBF binding two guanine bases, shown to be essential 
for MGF binding by contact point analysis [lo], were 
changed to cytosine in all three MPBF sites. This dra- 
matically reduced MPBF binding to the Al and A3S 
MPBF sites (T.B. et al., in prep.); however, two addi- 
tional bases, cytosines at positions - 100 and -99 had to 
be changed to T and G, respectively, to completely elim- 
inate MPBF binding to the high affinity STM site. 
Three constructs were selected for analysis in HCl 1 
cells: STM, in which the proximal STM site was 
changed; AlA3, in which the Al and A3S sites were 
modified; and SAA in which all thee MPBF sites were 
mutated. In addition, an NFlcB binding site at - 172 
which does bind an NFFcB-like activity in HCl 1 cells as 
judged by EMSA (data not shown), was also mutated 
using the PCR mutagenesis trategy (Fig. 1B). The CAT 
activity generated by unmodified and mutated BLG pro- 
moter-CAT constructs was measured in cytoplasmic ex- 
tracts from stably transfected HCll cells treated with 
either insulin or insulin, dexamethasone and PRL. The 
constructs were tested in three independently generated 
transfected pools of cells and the result of a representa- 
tive experiment is shown in Fig. 1C. Whilst mutation of 
the NFlcB site did not affect expression of the BLG 
promoter, mutation of MPBF sites significantly reduced 
CAT activity. Mutation of MPBF sites in the BLG-CAT 
constructs did not completely abolish the 3- to 4-fold 
Fig. 1. Generation and analysis of MPBF binding site mutations in the 
BLG promoter. (A) EMSA with nuclear extract (5 pg) from HCl I cells 
treated either with insulin alone (-) or with Dex and PRL (+), STM 
oligonucleotide probe and mutant MPBF binding site oligonucleotide 
competitors. The molar excess of cold competitor was 4-fold (lane 3) 
and 40-fold (lanes 4 and 5). (B) Schematic representation of the BLG 
promoter mutant constructs used in these experiments. Mutant binding 
site oligonucleotides were used to generate site-specific mutations by 
PCR. The sequences of these oligonucleotides are given in section 2. 
Construct STM has the proximal MPBF site mutated, construct Al A3 
has the two distal sites mutated and construct SAA has all three sites 
mutated. (C) Levels of CAT activity for HCI 1 cells transfected with the 
unmodified A Dp-BLG gene, and the four mutant constructs in re- 
sponse to insulin (solid bars), insulin and PRL (bold crosshatched bars), 
insulin and Dex (shaded bars), and insulin, Dex and PRL (faint cross- 
hatched bars).The means and standard deviations of triplicate samples 
for each treatment are shown. 
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hormonal induction of the BLG promoter. In the context 
of the normal sheep BLG gene, the SAA promoter is not 
hormonally induced in HCl cells 
The MPBF binding site is related to cytokinelgrowth 
factor response lements 
A comparison of the MPBF binding sites in the BLG 
promoter with a binding site for GAF (IFN-7 induced 
factor), the GAS motif from the Ly-6E gene [I 11, a high 
DEX+PRL - + + + + 
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Fig. 2. MPBF recognises GAS elements. (A) Comparison of the three 
MPBF binding sites in BLG with SIE, GAS, and APRE motifs (a high 
affinity variant of the c-for SIE element, the GAS site from the Ly-6E 
gene, and a high affinity variant of the APRF site, respectively). A
consensus equence is indicated - the single bases in the A3S and Al 
motifs which are not conserved are underlined. (B) Cross-competition 
of STM, SIE and GAS sequences. Competition titration of MPBF 
complex formation with 6 mg of lactating sheep mammary nuclear 
extract and either STM probe (upper panel) or SIE probe (lower panel) 
and increasing amounts of STM, SIE and GAS cold competitor ol- 
igonucleotides. A 5-fold (lanes 2, 6, IO), 15-fold (lanes 3, 7, 1 I), 30-fold 
(lanes 4, 8, 12), or 300-fold (lanes 5,9, 13) molar excess of the indicated 
cold oligonucleotide was added to the binding reaction and the amount 
of complex remaining relative to the uncompeted sample (lanes 1) 
quantitated with a phosphorimager. 
affinity SIE (sis-inducible element) variant which binds 
SIF [20], and a high affinity APRE site [12] which binds 
APRF (Stat3) shows that hese sites have a degree of 
dyad symmetry with the sequence at five positions abso- 
lutely conserved (shown in bold in Fig. 2A). Of the three 
BLG sites, STM is most similar to the GAS-related se- 
quences, matching exactly at seven positions and is al- 
most identical to the APRE variant motif. EMSA analy- 
sis showed that a mammary-specific complex of the same 
mobility as MPBF was observed with SIE and GAS 
oligonucleotide probes (data not shown). The relative 
affinity of MPBF for the STM, GAS, and SIE sites was 
determined by a competition EMSA in which either the 
STM or SIE elements were used as probe and all three 
180 T G. Burdon et al. I FEBS Letters 350 (1994) 177-182 
A 
pTpa* - + - - + + 
5 6 a 9 
Ab C Ptyr Ptyr Pser Pthr 
1 2 3 4 5 
Figure 3. MPBF is phosphorylated on tyrosine. (A) Treatment of 
MPBF from sheep (lanes 14) and mouse (lanes 5-9) lactating mam- 
mary glands with LAR (lane 9) and T-cell phosphatases (lanes 3, 4, 7 
and 8) and analysis by EMSA using STM probe. Treatment with 
phophatase, in the presence or absence of sodium vanadate inhibitor, 
are indicated above each lane. The samples with sheep extract con- 
tained Img of protein and those with the mouse extract contained 4 pg. 
(B) Inhibition of MPBF binding activity by antibodies directed against 
phosphotyrosine. Partially purified sheep MPBF (approximately 100 
ng) was incubated with either 5 gg control ascites antibodies (lane 1) 
or 2.5 pg (lane 2) or 5.0 pg (lane 3) of antiphosphotyrosine antibodies. 
binding site oligonucleotides were used as competitors 
(Fig. 2B). Quantitation of the retarded probe indicated 
that the affinity of MPBF for both the SIE and GAS sites 
was approximately five-fold lower than for the STM 
oligonucloetide. The affinity of MPBF for the GAS and 
SIE sites was similar to that for the BLG intermediate 
affinity A3S site (5 to 6-fold lower affinity than STM) 
but considerably higher than for the BLG Al motif (44- 
fold less than STM, [9]). MPBF did not bind an IFN-cr 
response element (ISRE) as judged by EMSA (Fig. 5B) 
indicating that MPBF recognises only a particular class 
of cytokine/growth factor response elements and sug- 
gests that MPBF may be related to the STAT family of 
transcription factors that bind GAS/SIE related se- 
quences. 
3.3. MPBF is phosphorylated on tyrosine 
To test whether MPBF requires tyrosine phosphoryla- 
tion for DNA binding activity, nuclear extracts from 
sheep and mouse lactating mammary gland were treated 
with either protein tyrosine phosphatases or with an- 
tiphosphotyrosine antibodies and analysed by EMSA. 
Treatment with either human T-cell or leukocyte antigen 
related (LAR) protein tyrosine phosphatase prior to 
EMSA reduced MPBF binding activity by 95% and 86% 
in mouse (Fig. 3A, lanes 5-9) and sheep (lanes 14) 
extracts respectively, and was inhibited by the specific 
tyrosine phosphatase inhibitor, sodium vanadate (lanes 
2, 4, 6 and 8)). Antibodies directed against phosphoty- 
rosy1 residues, also inhibited MPBF activity in partially 
purified sheep mammary nuclear extract by over 85% 
(Fig. 3B, lanes 2 and 3). Preimmune serum (lane l), 
antiphosphoserine (lane 4) and antiphosphothreonine 
(lane 5) antibodies did not inhibit MPBF complex for- 
mation under these conditions. These results indicate 
that tyrosine phosphorylation of MPBF or a component 
of the MPBF complex is required for maximal DNA 
binding activity. 
3.4. Molecular weight estimation of MPBFfrom 
the mammary glands of different species by 
UV cross-linking 
Fig. 4 (lane 1) shows that for sheep MPBF, two la- 
belled polypeptides of 83 and 85 kDa were cross-linked 
to the STM oligonucleotide (allowing 19 kDa for the 
cross-linked oligonucleotide). The molecular weight of 
the major labelled polypeptide in the mouse extract was 
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Figure 4. Identification of MPBF DNA-binding components by UV 
crosslinking. Lane 1 is the cross-linked MPBF polypeptides from 2 fig 
of lactating sheep nuclear extract, following electroelution, and frac- 
tionated on a SDS-PAGE gel. Lanes 24 are crosslinked MPBF com- 
plexes from lactating mammary nuclear extracts from sheep (OS pg), 
mouse (10 pg) and human (10 pg) respectively, run directly into an 
SDS-PAGE gel from the UV irradiated EMSA gel. 




Fig. 5. Analysis of components of MPBF. Nuclear extracts from lactating human mammary gland (4 pg) or IFN-a treated Daudi cells (5 pg) were 
incubated with p91/84 (Statl) or ~113 (Stat2) specific polyclonal antisera then radiolabelled STM (panel A) or ISRE (panel B) oligonucleotide probes 
added in a standard gel-shift assay. The source of extract and addition of antibody are indicated above each lane; M is lactating human mammary 
gland, DI is IFN-a induced and DU is uninduced Daudi cells. Preimmune serum (pi) was used as control. The positions of the MPBF, Stat1 and 
ISGF3 complexes are indicated. 
approximately 90 kDa. A more diffuse cross-linked band 
was obtained with MPBF from human extracts suggest- 
ing the presence of several proteins between 75 and 85 
kDa. The presence of multiple bands in human and 
sheep MPBF suggests that MPBF does not necessarily 
contain a single polypeptide of 89 kDa as described for 
rat MGF [ 181. The molecular weights of the cross-linked 
polypeptides in different species correlated with the rela- 
tive mobilities of MPBF complexes from these species in 
EMSA (data not shown). Overexposure of the gel (Fig. 
4, lanes 24) revealed additional high molecular weight 
complexes of 150-180 kDa, indicating that MPBF binds 
as a dimer to the palindromic STM site. A minor band 
of approximately 110 kDa was also detected in all the 
cross-linked samples. 
3.5. Stat1 and Stat2 are not components of MPBF 
Antibody binding experiments coupled with EMSAs 
were carried out to determine whether Stat1 and Stat2 
are components of the MPBF binding complex. Nuclear 
extract from lactating human mammary gland was used 
in these experiments to allow a direct comparison with 
the Stat 1 and ISGF-3 complexes induced by IFN-a treat- 
ment of Daudi cells. Nuclear extracts were incubated 
with antibodies specific for either Stat1 or Stat2 before 
EMSA with either STM or an ISRE (IFN-a stimulated 
response element) probe. The Stat 1 and Stat2 antibodies 
inhibited complexes formed on the GAS and ISRE 
probes respectively in Daudi nuclear extracts but did not 
affect binding of human MPBF (Fig. 5, lanes l-9). In 
addition, the mobilities of the MPBF and Stat1 com- 
plexes are clearly different. Western blots of nuclear ex- 
tracts also indicated that mammary nuclei contain very 
low levels of Stat1 (data not shown) supporting the con- 
clusion that Stat1 and Stat2 are not components of 
MPBF which may be a novel member of the STAT fam- 
ily. 
3.6. MPBF-like binding activity is induced directly by 
prolactin 
To determine whether PRL could induce MPBF bind- 
ing activity we utilised Chinese hamster ovary (CHO-E3) 
cells stably transfected with a vector that expresses the 
long form of the rabbit PRL receptor. This system has 
been used to demonstrate that the BLG promoter is 
stimulated by PRL [16, 211 and more recently to define 




Fig. 6. Prolactin induces MPBF binding activity in CHO-E3 cells. 
Nuclear extracts were prepared from CHO cells grown in either the 
absence (lane I) or presence (lanes 2-8) of PRL and 5 peg extract used 
in an EMSA with STM probe. Increasing amounts of cold STM or SIE 
competitor oligonucleotides were added to the binding reactions as 
indicated : IO-fold molar excess (lanes 3, 6), 20-fold excess (lanes 4, 7) 
and lOO-fold excess (lanes 5, 8). Lane 9 is an MPBF control using 8pg 
nuclear extract from lactating mouse mammary gland. This track was 
exposed for a shorter time than lanes I-8. 
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the prolactin response elements in the BLG promoter 
(Demmer et al., in prep.). A factor of similar mobility to 
mouse MPBF was induced 5- to IO-fold in the nuclear 
extracts of CHO-E3 cells treated with PRL. This factor 
bound the STM oligonucleotide specifically as demon- 
strated by titration with cold STM competitor binding 
sites. Competition with the SIE oligonucleotide demon- 
strated that the induced factor had a reduced affinity for 
this site compared with the STM oligonucleotide, anala- 
gous to the the result obtained with mammary gland 
derived MPBF (Fig. 2B). These results show that an 
MPBF-like binding activity can be stimulated by PRL 
alone and may mediate PRL signalling in tissues and 
cells other than the mammary gland. 
4. Discussion 
MPBF has several characteristics of the recently de- 
scribed STAT family of transcription factors. MPBF re- 
cognises Stat 1 binding sites, requires tyrosine phospho- 
rylation for DNA binding and may be composed of a 
dimer of an 80-90 kDa polypeptide. Five members of the 
STAT family of signalling factors have been cloned so 
far. In addition to Stat1 and Stat2, cDNA clones of 
mouse and human APRF (Stat3), mouse Stat4 and sheep 
MGF have been identified [22,23,24]. Although the high- 
est affinity binding site for MPBF, STM, is almost iden- 
tical to a high affinity variant of the APRF recognition 
element ([ 121 and Fig. 1 A) preliminary supershift experi- 
ments with an antibody to APRF indicate that MPBF 
does not contain Stat3 (data not shown). Since MGF has 
been shown to mediate the response to PRL and has 
binding sites in the promoter of the B-casein milk protein 
gene, it is likely that MGF and MPBF are similar factors. 
The finding that MPBF binds other STAT factor rec- 
ognition sequences suggests that STAT factors might 
regulate the BLG promoter through its MPBF sites. 
EGF is known to inhibit the expression of milk protein 
genes and can interfere in the induction of MGF in HCl 1 
cells [26] but the mechanism through which this effect is 
mediated is unknown. Since EGF can induce Stat 1 and 
Stat3, it is possible that these factors could directly an- 
tagonise milk protein gene expression by binding to 
MPBF and MGF sites. The identification of an MPBF- 
like complex in the virgin and early pregnant sheep mam- 
mary gland (CJW and TB, unpublished results), when 
the BLG gene is inactive, suggests that such a repressor 
might operate in vivo. 
Stat1 is the paradigm for a growing family of tran- 
scription factors which can be posttranslationally acti- 
vated in response to cytokines and growth factors. It will 
be interesting to determine the role these factors play in 
the regulation of mammary gland development and milk 
protein gene expression. 
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